- PTC to receive $1.0B in cash at closing - - PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones - - PTC to share profits in the U.S. and tiered double-digit ...

PTC Therapeutics signed a $1billion upfront deal with Novartis for its Huntington's program, with potential milestones of $1.9 billion. Interim Phase 2 data shows PTC518 reduces mutant protein levels ...

Novartis will pay PTC Therapeutics up to $2.9 billion for its oral therapy to treat Huntington’s disease in a deal announced Monday morning. As part of the agreement, PTC Therapeutics will receive $1 ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — Novartis is paying $1 billion upfront in a licensing deal for an ...

(RTTNews) - Biopharmaceutical company PTC Therapeutics, Inc. (PTCT) announced Monday the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corp., a ...

PTC Therapeutics (NASDAQ:PTCT) shares jumped around 21% Monday morning after it inked an exclusive global license and collaboration agreement with Novartis Pharmaceuticals (NYSE:NVS) for its PTC518 ...